Protherics
Runcorn
About Protherics
Protherics is a biopharmaceutical company that develops, manufactures and markets specialized hospital products for critical care and cancer primarily in the United Kingdom, the United States, and Australia. The company offers various products for application in medical emergencies, such as overdose, poisoning, and life-threatening infections. It offers critical care products, which include CroFab, a polyclonal antibody fragment that neutralizes venom from North American Crotalid snakes; DigiFab, a polyclonal antibody fragment for the treatment of life-threatening digoxin toxicity or overdose; CytoFab, which is used in the treatment of severe sepsis; and ViperaTAb, a venom antidote product for the treatment of snakebites; and Digoxin Immune Fabs, which are polyclonal antibody fragments used in the treatment of pre-eclampsia, a complication of pregnancy.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Website: protherics.com
- Phone: 44 19 2851 8000
Industries & Categories
Biotechnology, Health Care, Hospital, Life Science, Manufacturing
Social Profiles
Canonical: https://fsome.com/organization/protherics-3801311 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.